The Supreme Court's decision on Markman will impact your biotechnology company if there is an infringement trial.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
McGill Inc. v. John Zink Co., 746 F.2d 666, (Fed. Cir. 1984).
35 U.S.C. §112, ¶1
US Patent ♯ 4965204 at issue in Johns Hopkins University v Cellpro 894 F.Supp.819.
35 U.S.C.§112, ¶2
Read Corp v. Portec, Inc., 970 F.2d 816, 821, 23 U.S.P.Q.2d 1426,1431 (Fed.Cir. 1992).
Id.
See Arnold, A Historical Inquiry into the Right to Trial by Jury in Complex Civil Litigation, 28 U. Pa. L. Rev. 829 (1980); see also SRI International v. Matsushita Electric Corp. of America, 775 F.2d 1107, 227 U.S.P.Q. 577 (Fed. Cir. 1985).
Markman v. Westview Instr., Inc., 52 F.3d 967, (Fed.Cir. 1995) (en banc).
Id at 979.
Id.
Exxon Chemical Patent, Inc., v. Lubrizol Corporation, 64 F.3d 1553, 35 U.S.P.Q.2d 1801 (Fed.Cir. Sept. 1, 1995).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rzucidlo, E., Auth, D. What Markman should mean to you. Nat Biotechnol 14, 888–890 (1996). https://doi.org/10.1038/nbt0796-888
Issue Date:
DOI: https://doi.org/10.1038/nbt0796-888